Literature DB >> 28882943

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts.

Raelene A VAN Noord1, Tina Thomas1, Melanie Krook2, Sahiti Chukkapalli1, Mark J Hoenerhoff3, Jonathan R Dillman4, Elizabeth R Lawlor2,5, Valerie P Opipari5, Erika A Newman6.   

Abstract

BACKGROUND: Advances in cancer therapeutics depend on reliable in vivo model systems. To develop biologically relevant xenografts, ultrasound was utilized for tissue-directed implantation of neuroblastoma (NB) cell line and patient-derived tumors in the adrenal gland, and for renal subcapsular engraftment of Ewing's sarcoma (ES).
MATERIALS AND METHODS: NB xenografts were established by direct adrenal injection of luciferase-transfected NB cell lines (IMR32, SH-SY5Y, SK-N-BE2) or NB patient-derived tumor cells (UMNBL001, UMNBL002). ES xenografts were established by renal subcapsular injection of TC32, A673, CHLA-25, or A4573 cells. Progression was monitored by in vivo imaging.
RESULTS: Tumors progressed to local disease with metastasis evident by 5 weeks. Metastatic sites included cortical bone, lung, liver, and lymph nodes. Xenografted tumors retained immunochemical features of the original cancer.
CONCLUSION: Human NB adrenal xenografts, including two patient-derived orthotopic, and ES renal subcapsular xenografts were established by ultrasound without open surgery. Tissue-directed implantation is an effective technique for developing metastatic preclinical models. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Ewing's sarcoma; neuroblastoma; orthotopic; preclinical model; ultrasound; xenograft

Mesh:

Year:  2017        PMID: 28882943      PMCID: PMC5656850          DOI: 10.21873/invivo.11131

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  23 in total

Review 1.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Authors:  M F Sanmamed; C Chester; I Melero; H Kohrt
Journal:  Ann Oncol       Date:  2016-02-23       Impact factor: 32.976

Review 2.  Mouse Models of Tumor Immunotherapy.

Authors:  Shin Foong Ngiow; Sherene Loi; David Thomas; Mark J Smyth
Journal:  Adv Immunol       Date:  2016-01-19       Impact factor: 3.543

Review 3.  Patient-derived xenografts as tools in pharmaceutical development.

Authors:  E Izumchenko; J Meir; A Bedi; P T Wysocki; M O Hoque; D Sidransky
Journal:  Clin Pharmacol Ther       Date:  2016-03-09       Impact factor: 6.875

4.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

Review 5.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

Authors:  M C Bibby
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

Review 6.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Authors:  Kristopher R Bosse; John M Maris
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

7.  ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.

Authors:  Alan K Ikeda; Dejah R Judelson; Noah Federman; Keith B Glaser; Elliot M Landaw; Christopher T Denny; Kathleen M Sakamoto
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

8.  Preclinical models for neuroblastoma: establishing a baseline for treatment.

Authors:  Tal Teitz; Jennifer J Stanke; Sara Federico; Cori L Bradley; Rachel Brennan; Jiakun Zhang; Melissa D Johnson; Jan Sedlacik; Madoka Inoue; Ziwei M Zhang; Sharon Frase; Jerold E Rehg; Claudia M Hillenbrand; David Finkelstein; Christopher Calabrese; Michael A Dyer; Jill M Lahti
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

Authors:  William A May; Rita S Grigoryan; Nino Keshelava; Daniel J Cabral; Laura L Christensen; Jasmine Jenabi; Lingyun Ji; Timothy J Triche; Elizabeth R Lawlor; C Patrick Reynolds
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

10.  Minimally invasive establishment of murine orthotopic bladder xenografts.

Authors:  Wolfgang Jäger; Igor Moskalev; Claudia Janssen; Tetsutaro Hayashi; Killian M Gust; Shannon Awrey; Peter C Black
Journal:  J Vis Exp       Date:  2014-02-11       Impact factor: 1.355

View more
  1 in total

1.  Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts.

Authors:  Tina T Thomas; Sahiti Chukkapalli; Raelene A Van Noord; Melanie Krook; Mark J Hoenerhoff; Jonathan R Dillman; Elizabeth R Lawlor; Valerie P Opipari; Erika A Newman
Journal:  J Vis Exp       Date:  2018-05-25       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.